The next generation biopharmaceuticals

Scientific Advisory Board

Prof. Hans Wigzell, M.D., Ph.D.
Professor Emeritus of Microbiology and Tumor Biology, Karolinska Institutet

Prof. Mathias Uhlén, Ph.D.
Professor of Microbiology, Royal Institute of Technology

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

  • Interim Report January to March 2020 (May 15, 2020)
  • Interim Report January to June 2020 (August 21, 2020)
  • Interim Report January to September 2020 (November 13, 2020)
  • Year End Report 2020 (February 2021)